Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

54.74
-1.2300-2.20%
Post-market: 54.750.0100+0.02%17:46 EST
Volume:1.17M
Turnover:65.58M
Market Cap:5.22B
PE:-9.80
High:58.00
Open:55.74
Low:54.60
Close:55.97
52wk High:78.48
52wk Low:30.04
Shares:95.30M
Float Shares:90.53M
Volume Ratio:0.83
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5830
EPS(LYR):-4.3416
ROE:-25.33%
ROA:-13.28%
PB:2.72
PE(LYR):-12.61

Loading ...

CRISPR Therapeutics Ag : Barclays Raises Target Price to $56 From $42

THOMSON REUTERS
·
Aug 06

Stock Track | CRISPR Therapeutics Soars 5.32% on Positive Analyst Ratings and ARK Investment's Large Purchase

Stock Track
·
Aug 06

Crispr Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 06

RBC Raises Price Target on CRISPR Therapeutics to $42 From $38, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Aug 05

BUZZ-Crispr Therapeutics falls after weak quarterly results

Reuters
·
Aug 05

Stock Track | CRISPR Therapeutics Plunges 8.86% Pre-Market on Q2 Revenue Miss and Widened Losses

Stock Track
·
Aug 05

Stock Track | CRISPR Therapeutics Plunges 8.46% as Q2 Revenue Misses Estimates, Net Loss Widens

Stock Track
·
Aug 05

CRISPR Therapeutics Ag : RBC Raises Target Price to $42 From $38

THOMSON REUTERS
·
Aug 05

CORRECTION: CRISPR Therapeutics Q2 Adj. EPS $(1.29) Beats $(1.47) Estimate, Sales $892.000K Miss $6.255M Estimate

Benzinga
·
Aug 05

CRISPR Therapeutics Q2 EPS $(2.40) Down From $(1.49) YoY

Benzinga
·
Aug 05

CRISPR Therapeutics Q2 revenue misses estimates, net loss widens

Reuters
·
Aug 05

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Hershey, Wingstop

Reuters
·
Jul 30

BUZZ-U.S. STOCKS ON THE MOVE-Visa, Kraft Heinz, Humana

Reuters
·
Jul 30

Crispr Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Jul 23

CRISPR Therapeutics Pick of the Week at Smart Insider Following Simeon George's Stock Purchase

MT Newswires Live
·
Jul 22

AI Biotech Stocks Shined. Recursion Soared 10%; Absci Up 7%; Crispr Up 6%; Beam And Ginkgo Up 3%

Tiger Newspress
·
Jul 21

CRISPR Therapeutics AG Director George Simeon Reports Acquisition of Common Shares

Reuters
·
Jul 18

Crispr Therapeutics Price Target Maintained With a $81.00/Share by Needham

Dow Jones
·
Jul 08

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 08

Crispr Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 27